Guardant Health Inc.
Guardant Health's Shield Blood Test Approved by FDA for CRC Screening
Summary
Guardant Health, Inc. announced on July 29, 2024, that the U.S. Food and Drug Administration (FDA) has approved the Company's Shield blood test to screen for colorectal cancer in adults age 45 and older who are at average risk for the disease. This approval makes Shield the first blood test to be approved by the FDA as a primary screening option for colorectal cancer, enabling healthcare providers to offer it as a convenient alternative to other non-invasive screening methods. The approval is based on results from a registrational study with over 20,000 patients, demonstrating the test's 83% sensitivity and 90% specificity for detecting colorectal cancer. The Shield test is expected to be covered for eligible Medicare beneficiaries and will likely expand commercial insurance coverage following anticipated guideline inclusion by major health organizations.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement